Navigation Links
Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace
Date:11/26/2007

Thought-leaders Josh Ofman, Steve Phurrough, Larry Kocot and Robert Seidman Headline Agenda at FDA/CMS Summit 2007

WASHINGTON, Nov. 26 /PRNewswire-USNewswire/ -- Value-based medicine has progressed beyond a topic of industry insider buzz to become a functional buying model adopted by public and private payers. Value isn't a new concept in the consumer marketplace, but what does it mean for buying and selling biopharmaceuticals? How is value calculated, and what are the variables? From setting prices to securing reimbursement, the valuation of treatments is tougher than ever to crack. And the stakes have never been higher with shrinking pipelines and tighter bottom lines. Getting the value calculation right can be the difference between success and failure of a new therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071126/DC08207 )

The FDA/CMS Summit, taking place December 6-7 in Washington, D.C., will feature key decision makers from government and industry to help biopharmaceutical executives understand how the value calculation is shifting, and what those changes mean for commercial success.

"Today, the value of a therapy is determined by more players than ever before, looking at more data than ever before. The threshold is a moving target for biopharmaceutical executives seeking reimbursement," said Cole Werble, editor-in-chief of The RPM Report, the conference organizer. "Learning what payers are looking at when making decisions early on can help industry come to market with successful products that are appropriately reimbursed. The FDA/CMS Summit provides leaders in industry key insight from reimbursement policy-makers who make purchasing and pricing decisions."

The FDA/CMS Summit provides health care executives with an exclusive opportunity to have face-to-face dialogues with top policymakers and executives. The Summit is aimed at industry executives in all areas of responsibility who want to create successful strategies for dealing with FDA and CMS. Attendees will get practical, real-life lessons from some of the most experienced pharmaceutical and biotechnology executives on handling regulatory obstacles and on identifying opportunities in the current dynamic environment. The conference will also provide a forum for attendees to benchmark their regulatory strategy against all other pharmaceutical and biotechnology companies.

Among the panels and participants scheduled to address value of medicine during the Summit are:
-- Personalized Medicine: How Industry and Government Can Make it Happen

George Abercrombie - CEO, Hoffmann La-Roche, Inc.

-- Keynote Address

Tevi D. Troy - Deputy Secretary, HHS

-- Paying for Innovation: CMS' Approach to Coverage

Steve Phurrough - CMS Coverage & Analysis Group Director

-- Coverage Policy and Value Demonstration - An Industry Perspective

Josh Ofman - VP Global Reimbursement, Amgen

-- How the Government and Payors will Impact the Rx Market

Larry Kocot - Former CMS Senior Advisor

Robert Seidman - Former Wellpoint Chief Pharmacy Officer and Founder

of Doc Rock Presents

-- Pharmaceutical Pricing Legislation: What does Industry Need to do to

Prepare?

Brian Cohen - House Oversight and Government Reform Committee Staff

Stephen Schondelmeyer, Pharm.D., Ph.D. - Director, PRIME Institute

Joseph R. Antos - Wilson H. Taylor Scholar on Health Care and

Retirement Policy, American Enterprise Institute

Complete agenda and registration information are available at http://www.windhover.com/fda-cms.

The RPM Report is a unique Windhover publication that examines FDA and CMS from a business perspective, designed to deliver not only the news from FDA and CMS but to tell executives what it all means to their companies. Register for a free online trial or a complimentary issue at http://www.rpmreport.com.

Sponsors for the FDA/CMS summit are Foley Hoag LLP, Ogilvy Public Relations Worldwide, Avalere Health, and the Personalized Medicine Coalition.

Media sponsors are pharmalicensing.com, and bioscreening.com.

About Windhover Information

Windhover Information Inc. has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and audio conferences. For more on the company's products and services, please see http://www.windhover.com.


'/>"/>
SOURCE Windhover Information Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. ZIP codes and property values predict obesity rates
2. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
3. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
4. Cincinnati Adoption Agency Invited to Participate in Values Voter Presidential Debate
5. Study Questions Flu Shots Value for Older People
6. Glycemic index values are variable, report researchers
7. Medco Unveils Three New Medicare Prescription Drug Plan Options for 2008 to Provide Seniors More Choice, Better Value and Specialist Pharmacists
8. Boston Scientific Announces New Initiatives to Increase Shareholder Value
9. Value of Most Post-Traumatic Stress Treatments Uncertain
10. Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer
11. What is a critical lab value? it depends, Hopkins researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 bottles ... AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while doing ... an over the counter heart healthy drink, can reduce Arterial Plaque, Lower Blood ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... growing as it continues developing an ANSI-approved, consensus-based American National Standard for ... plans to publish the first ANSI-approved GMP standard for dietary supplements this ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an ... 20, 2017, at 1:00 PM ET. A recording of the webinar will also be ... Series. , Home health and hospice companies are still popular targets for healthcare investors. ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who ... at Intercontinental Time Square, New York. , The program will be led ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... their offering. ... The ablation device global market is expected to grow at high ... Ablation is the minimally invasive therapeutic tissue excision procedure used ... removal, to the removal of abnormally conducting cardiac tissue in atrial ...
(Date:3/29/2017)... , March 29, 2017  Spiral Therapeutics, ... agreement with Bionure Farma, S.L. for the worldwide ... to BN119 in the field of otolaryngology for ... sales-based royalties. The agreement provides Spiral with ... with a differentiated product profile. Under the terms ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology: